Literature DB >> 27761482

Immunology of neuromyelitis optica during pregnancy.

Vahid Davoudi1, Kiandokht Keyhanian1, Riley M Bove1, Tanuja Chitnis1.   

Abstract

Anti-aquaporin-4 (AQP4) autoantibody plays a key role in the pathogenesis of neuromyelitis optica (NMO). Studies have shown increased relapse rates in patients with NMO during pregnancy and postpartum. High estrogen levels during pregnancy can increase activation-induced cytidine deaminase expression, which is responsible for immunoglobulin production. Additionally, sex hormones may influence antibody glycosylation, with effects on antibody function. Estrogen decreases apoptosis of self-reactive B cells, through upregulation of antiapoptotic molecules. Furthermore, high estrogen levels during pregnancy can boost B-cell activating factor and type 1 interferon (IFN) production, facilitating development of self-reactive peripheral B cells in association with increased disease activity. Elevated levels of estrogen during pregnancy decrease IFN-γ generation, which causes a shift toward T helper (Th) 2 immunity, thereby propagating NMO pathogenesis. Women with NMO have an elevated rate of pregnancy complications including miscarriage and preeclampsia, which are associated with increased Th17 cells and reduction of T-regulatory cells. These in turn can enhance inflammation in NMO. Increased regulatory natural killer cells (CD56-) during pregnancy can enhance Th2-mediated immunity, thereby increasing inflammation. In the placenta, trophoblasts express AQP4 antigen and are exposed to maternal blood containing anti-AQP4 antibodies. Animal models have shown that anti-AQP4 antibodies can bind to AQP4 antigen in placenta leading to complement deposition and placental necrosis. Reduction of regulatory complements has been associated with placental insufficiency, and it is unclear whether these are altered in NMO. Further studies are required to elucidate the specific mechanisms of disease worsening, as well as the increased rate of complications during pregnancy in women with NMO.

Entities:  

Year:  2016        PMID: 27761482      PMCID: PMC5056648          DOI: 10.1212/NXI.0000000000000288

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


  60 in total

1.  Outcome of lupus pregnancy: a controlled study.

Authors:  P E Georgiou; E N Politi; P Katsimbri; V Sakka; A A Drosos
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

2.  Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.

Authors:  Julien Ratelade; Hua Zhang; Samira Saadoun; Jeffrey L Bennett; Marios C Papadopoulos; A S Verkman
Journal:  Acta Neuropathol       Date:  2012-04-22       Impact factor: 17.088

3.  The impact of increased lupus activity on obstetric outcomes.

Authors:  Megan E B Clowse; Laurence S Magder; Frank Witter; Michelle Petri
Journal:  Arthritis Rheum       Date:  2005-02

4.  Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice.

Authors:  Grant C Hughes; David Martin; Kang Zhang; Kelly L Hudkins; Charles E Alpers; Edward A Clark; Keith B Elkon
Journal:  Arthritis Rheum       Date:  2009-06

5.  Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia.

Authors:  Brigitte Santner-Nanan; Michael John Peek; Roma Khanam; Luise Richarts; Erhua Zhu; Barbara Fazekas de St Groth; Ralph Nanan
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

6.  Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice.

Authors:  J R Roubinian; N Talal; J S Greenspan; J R Goodman; P K Siiteri
Journal:  J Exp Med       Date:  1978-06-01       Impact factor: 14.307

7.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

8.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

9.  Gaze palsy, hypogeusia and a probable association with miscarriage of pregnancy--the expanding clinical spectrum of non-opticospinal neuromyelitis optica spectrum disorders: a case report.

Authors:  Thashi Chang; Milinda Withana
Journal:  BMC Res Notes       Date:  2015-02-10

10.  Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype.

Authors:  Charlotte Gustafsson; Jenny Mjösberg; Andreas Matussek; Robert Geffers; Leif Matthiesen; Göran Berg; Surendra Sharma; Jan Buer; Jan Ernerudh
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

View more
  19 in total

1.  Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.

Authors:  Tetsuya Akaishi; Toshiyuki Takahashi; Kazuo Fujihara; Tatsuro Misu; Juichi Fujimori; Yoshiki Takai; Shuhei Nishiyama; Michiaki Abe; Tadashi Ishii; Masashi Aoki; Ichiro Nakashima
Journal:  J Neurol       Date:  2021-01-08       Impact factor: 4.849

Review 2.  Headache in Neuromyelitis Optica.

Authors:  Alina Masters-Israilov; Matthew S Robbins
Journal:  Curr Pain Headache Rep       Date:  2017-04

Review 3.  Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies.

Authors:  Nadja Borisow; Kerstin Hellwig; Friedemann Paul
Journal:  EPMA J       Date:  2018-08-10       Impact factor: 6.543

4.  Identification of Novel Serum Proteins Associated with Myelination and Cholesterol Transport in Neuromyelitis Optica Spectrum Disorders by Mass Spectrometry.

Authors:  Mathew John; Evelyn Maria; Sonu Das; Harisuthan T
Journal:  Indian J Clin Biochem       Date:  2021-11-12

Review 5.  [Neuromyelitis optica spectrum disorder and pregnancy].

Authors:  N Borisow; K Hellwig; F Paul
Journal:  Nervenarzt       Date:  2018-06       Impact factor: 1.214

Review 6.  Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations.

Authors:  Yang Mao-Draayer; Sandra Thiel; Elizabeth A Mills; Tanuja Chitnis; Michelle Fabian; Ilana Katz Sand; M Isabel Leite; Sven Jarius; Kerstin Hellwig
Journal:  Nat Rev Neurol       Date:  2020-02-20       Impact factor: 42.937

Review 7.  Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.

Authors:  Joseph Kuchling; Alexander U Brandt; Friedemann Paul; Michael Scheel
Journal:  EPMA J       Date:  2017-07-25       Impact factor: 6.543

Review 8.  Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.

Authors:  Zhen Wang; Yaping Yan
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

9.  Insights into Initial Demyelinating Episodes of Central Nervous System during Puerperium.

Authors:  Qian Wu; Bo Chen; Na Liu; Yang Hu; Chao Pan; Ping Zhang; Zhou-Ping Tang; Bi-Tao Bu
Journal:  Chin Med J (Engl)       Date:  2017-08-05       Impact factor: 2.628

10.  Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.

Authors:  Gitanjali Das; Vincent Damotte; Jeffrey M Gelfand; Carolyn Bevan; Bruce A C Cree; Lynn Do; Ari J Green; Stephen L Hauser; Riley Bove
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.